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  ・ Pulmonary function test requires patients’ effort in idiopathic pulmonary 
fibrosis 
 ・Forced oscillation technique can be noninvasively performed during normal 
breathing 
 ・Results of forced oscillation technique and pulmonary function test were 
correlated 
 ・Respiratory reactance predicted subsequent lung capacity deterioration  
 ・Respiratory reactance reflects disease severity in idiopathic pulmonary fibrosis 
 
Abstract 
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease . 
Although pulmonary function test (PFT) is useful for evaluating the progression of IPF, 
obtaining adequate results in advanced cases can be challenging. Conversely, the forced 
oscillation technique (FOT) can be noninvasively performed, even in patients with 
severely deteriorated lung function. In this study, the usefulness of FOT for the 
evaluation of IPF disease status was investigated. 
Methods: We analyzed the PFT and FOT data of 97 patients with IPF. 
Results: The respiratory reactance (Xrs) components of FOT, especially in the 
inspiratory phase, correlated with the PFT values. Patients with advanced disease had 
significantly lower reactance at 5 Hz (X5), higher resonant frequency (Fres) and low-
frequency reactance area (ALX). The longitudinal deterioration of Xrs was also 













Conclusion: The Xrs components of FOT, especially in the inspiratory phase, reflected 
restrictive ventilatory impairment and disease severity in patients with IPF. 
 
 
Keywords: Forced oscillation technique, Lung physiology, Interstitial lung disease, 















Interstitial lung disease (ILD) is a generic term for diseases that present with 
inflammation and fibrosis in the alveolar septum, causing restrictive ventilatory 
impairment (American Thoracic Society et al., 2002). Idiopathic pulmonary fibrosis 
(IPF) is the most common phenotype of ILD and has a chronic progressive course with 
poor prognosis (Raghu et al., 2011). In patients with IPF, the pulmonary function test 
(PFT) variables, including vital capacity (VC), forced vital capacity (FVC), and 
diffusing capacity of the lung for carbon monoxide (DLCO), have been associated with 
prognosis (Martinez and Flaherry, 2006). The gender, age, and physiologic (GAP) 
disease staging model, which is scored by gender, age, FVC percent predicted (%FVC) 
and DLCO percent predicted (%DLCO), has been widely used for the prognostication 
of patients with IPF (Ley B et al., 2012). Although PFT is important in IPF management, 
it requires breathing effort from patients and sometimes cannot be successfully 
performed, owing to severely deteriorated lung capacity or advanced age. 
The forced oscillation technique (FOT) applies the pulse or artificial noise 
vibration that is electrically generated in the air to the intraoral direction of the subject 
and measures the returning airflow and intraoral pressure. This device enables 
quantitative evaluation of the mechanical factors, such as viscous resistance due to 
friction and elasticity or inertia of the airway and air, which prevent ventilation 
(Oostveen E et al., 2003). Moreover, FOT allows noninvasive measurement of 
respiratory resistance and reactance during normal breathing, even in patients with 
severely impaired lung function. 
Respiratory impedance (Zrs), which is measured during FOT, can be divided into 













Zrs2 = Rrs2 ＋ Xrs2 
 
Rrs was reported to reflect airway caliber, whereas Xrs was considered to indicate the 
elasticity and inertia of the respiratory system (Shirai and Kurosawa, 2016). 
FOT has been widely used for the evaluation of disease status and drug efficacy 
in obstructive pulmonary diseases, such as chronic obstructive pulmonary disease 
(COPD) and bronchial asthma, and many studies have confirmed its usefulness (Dellaca 
RL et al., 2004; Paredi P et al., 2010; Shirai T et al., 2013; Mikamo M et al., 2013). On 
the other hand, only few reports have shown the usefulness of FOT in ILD (van Noord 
JA et al., 1989; Sugiyama A et al., 2013; Fujii M et al., 2015). Moreover, to the best of 
our knowledge, there have been no reports that focused on the use of FOT in IPF. 
In this study, the usefulness of FOT was evaluated by investigating the 
relationship between PFT and FOT results, the differences in FOT values according to 
disease stage, and the longitudinal change in FOT values in patients with IPF. 
 
 
2. Material and methods 
2.1. Subjects 
A total of 113 patients with IPF and who have undergone PFT and FOT at the 
Sapporo Medical University Hospital from March 2012 to March 2017 were 
retrospectively investigated. IPF was diagnosed by a committee that comprised three 
ILD specialists, based on the 2011 American Thoracic Society/European Respiratory 
Society/Japanese Respiratory Society/Latin American Thoracic Association statement 
(Raghu G et al., 2011). Patients who had lung cancer and/or those who underwent lung 











which was diagnosed according to the criteria by Cottin et al. (Cottin V et al., 2005), 
were also excluded from the study. A total of 97 patients with IPF were finally included 
in this study. This study was conducted in accordance with the Declaration of Helsinki 
and was approved by the institutional review board of the Sapporo Medical University 
Hospital (approval number 282-236; ref. April 13, 2017). 
 
2.2. Measurement of respiratory impedance and PFT 
  Respiratory impedance was measured with a broadband FOT using MostGraph-01 
(Chest M.I. Co., Ltd, Japan) and met the standard recommendations (Oostveen E et al., 
2003). Impulse oscillatory signals that were generated by a loud speaker were applied 
to the respiratory system through the mouthpiece during tidal breathing for 
approximately 30 seconds. During the measurements, the subjects supported their 
cheeks to reduce upper airway shunting and were asked to wear a nose clip to avoid air 
leaks while sitting with their neck in a comfortable neutral posture.  In this study, we 
measured and analyzed Rrs at 5 Hz (R5) and 20 Hz (R20), the difference between R5 
and R20 (R5–R20), Xrs at 5Hz (X5), resonant frequency (Fres), and low-frequency 
reactance area (ALX). Oscillatory indices were expressed as the mean value during a 
respiratory cycle (whole breath), expiratory phase (Ex), inspiratory phase (In), and 
difference between expiratory and inspiratory phases (Δ). 
 VC, FVC, forced expiratory volume in one second (FEV1), and DLCO were 
measured using CHESTAC-8900 (Chest M.I. Co., Ltd, Japan), according to 
recommendations (Miller et al., 2005). FOT and PFT were performed on the same day, 
and FOT measurements were performed before PFT. 
 












Correlation between the PFT and FOT values was investigated using the 
Spearman's rank correlation coefficient. For patients who underwent several PFT and 
FOT evaluations, the initial measurement was used. 
 
2.4. PFT and FOT values according to IPF disease severity 
Based on the GAP disease stage (Ley B et al., 2012), patients with IPF were 
classified in two groups: GAP stage I (n = 47) and GAP stage II/III (n = 50). The PFT 
and FOT results were compared between the two groups using the Mann–Whitney U 
test. 
 
2.5. Longitudinal variations of the PFT and FOT values 
Next, we assessed the longitudinal variations in PFT and FOT in patients who 
underwent the evaluations more than twice. The test values at the initial and second 
measurements were evaluated. Because the interval from the initial to the second 
measurement differed between cases, patients with a measurement interval of 12 ± 3 
months were included in the longitudinal analysis (n = 41). For each patient, the initial 
PFT and FOT values were compared with the second values using the Wilcoxon signed-
rank test. 
 
2.6. Predictive factors of ≥10% FVC decline 
Additionally, the predictors of FVC decline after 12 months from when the initial 
measurements were investigated. Cases in which the interval between the initial and 
second measurements of PFT and FOT was 12 ± 3 months were included in this analysis 
(n = 41). Patients were divided into two groups according to the rate of FVC decline 














FVC decline rate (%) = (Second value − Initial value)/ Initial value × 100 
 
Logistic regression analyses were performed to identify the predictive factors of ≥10% 
FVC decline. The variables used in the univariate analysis included age, gender, 
smoking status, DLCO, %DLCO, and FOT values. The values that had p values of <0.20 
in the univariate analysis were included in the multivariate analysis. 
 
2.7. Statistical analysis 
Statistical analyses were performed using SPSS Statistics software (SPSS 
Statistics Version 22; IBM, Chicago, IL) and GraphPad Prism v7 software (GraphPad, 




3.1. Baseline characteristics 
The baseline characteristics of the study population are shown in Table 1. The 
median age of the patients was 72 years [interquartile range (IQR), 67–77 years]; 73 
were men and 24 were women. The median values for Brinkman index, body mass 
index, %FVC, and %DLCO were 700 (IQR, 150–1010), 23.5 (IQR, 21.5–25.9), 86.0 % 
(IQR, 71.1–98.1%), and 53.4 % (IQR, 43.6–63.0%), respectively. 
 
3.2. Correlations between the PFT and FOT values 












breath, In) showed significant negative correlations with the VC, FVC, and FEV1 (Table 
2). The X5 (whole breath, Ex, In) showed significant positive correlations with the 
VC, %VC, FVC, %FVC, and FEV1, whereas the Fres (whole breath, Ex, In) and ALX 
(whole breath, Ex, In) showed significant negative correlations with the VC, %VC, 
FVC, %FVC, and FEV1 (Table 2). In particular, the Xrs values in the inspiratory phase 
demonstrated strong correlations with the VC, %VC, FVC, and %FVC (r = 0.5–0.6, p 
<0.01) (Figure 1). Additionally, a positive correlation was found between X5 (whole 
breath, In) and DLCO, and Fres (whole breath, In) and ALX (whole breath, In) were 
negatively correlated with DLCO. 
 
3.3. Comparison between the PFT and FOT values according to GAP disease stage 
On PFT, the VC, %VC, FVC, %FVC, FEV1, DLCO, and %DLCO were 
significantly lower in the GAP stage II/III than in the GAP stage I group. No significant 
Rrs difference was found between both groups. Conversely, X5 (whole breath, In) was 
significantly lower, whereas Fres (whole breath, Ex, In) and ALX (whole breath, In) 
were significantly higher in the GAP stage II/III than in the GAP stage I group (Table 
3). 
 
3.4. Comparison between the initial and second values of PFT and FOT 
Among the patients included in the longitudinal analysis, the median duration of 
the initial and second measurements was 12 months (range, 11–15 months; IQR, 11–13 
months). In the longitudinal analysis, VC, %VC, FVC, %FVC, FEV1, DLCO, 
and %DLCO significantly decreased, whereas FEV1/FVC significantly increased (Table 
4). Although no significant change was observed in the Rrs during the clinical course, 












ALX (whole breath, Ex, In) significantly increased. 
 
3.5. Predictive factors of FVC decline over 12 months 
On univariate analysis, the Xrs values in the inspiratory phase were significantly 
associated with ≥10% FVC decline over 12 ± 3 months (p <0.05) (Table 5). Because 
almost all Xrs indices had p values of <0.20 and were found to be strongly correlated (r 
= 0.8–0.9), X5 (In) was included in the multivariate analysis as the representative index 
of Xrs. The multivariate analysis revealed that low X5 (In) was significantly associated 
with ≥10% FVC decline over 12 ± 3 months [odds ratio (OR) 0.137, 95% CI 0.021–




IPF is a chronic progressive disease of unknown etiology and has a poor 
prognosis (Natsuizaka et al., 2014). The PFT variables VC, FVC, and DLCO have 
been used to evaluate disease status (Travis et al., 2013) and were reported to predict 
the prognosis of patients with IPF (Martinez and Flaherry, 2006). However, some 
patients with advanced disease have difficultly performing PFT, which requires effort 
and a certain amount of VC to measure DLCO. Therefore, appropriate results cannot 
be obtained occasionally. On the other hand, FOT can be noninvasively performed 
during normal breathing, even in advanced cases. 
In this study, the PFT and Xrs on FOT values were strongly correlated, 
particularly when Xrs was measured in the inspiratory phase. Moreover, the Xrs values 
predicted ≥10% FVC decline over 12 months after performing FOT. Due to the short 












predicted the prognosis of patients with IPF. Nevertheless, ≥10% FVC decline has been 
reported to predict mortality in patients with IPF (Du Bois et al., 2011; Richeldi et al., 
2012) and has been used as the primary endpoint in a pirfenidone clinical trial (King et 
al., 2014). Therefore, Xrs values, especially in the inspiratory phase, may be used as a 
PFT substitute to predict disease progression and the prognosis of patients with IPF. 
The usefulness of FOT to evaluate the disease status in patients with IPF was also 
examined in the present study. Sugiyama et al. (2013) evaluated the differences in FOT 
values between healthy volunteers and patients with ILD, bronchial asthma, and COPD; 
they reported that patients with ILD showed lower X5 and higher Fres and ALX, 
compared with those in the healthy controls. In this study, comparison between GAP 
stage I and stage II/III revealed that X5 decreased and Fres and ALX increased as the 
disease stage progressed. Moreover, these values deteriorated in the longitudinal 
analysis. For the Xrs, three indices are mainly used: X5, which is Xrs at 5 Hz; Fres, 
which is the resonant frequency at point 0; and ALX, which is the low-frequency area 
(integral from X5 to Fres). These indices were reported to reflect lung parenchymal and 
airway abnormalities. X5 is considered the reciprocal of lung compliance, and its value 
becomes more negative when the lung tissue has reduced compliance (Sugiyama et al., 
2013). In addition, Fres reflects progression of lung fibrosis and increase in lung elastic 
recoil in ILD (Shirai and Kurosawa, 2016). According to these reports, X5 decrease, 
Fres increase, and ALX increase may be considered to indicate the progression of lung 
fibrosis in IPF. 
In this study, patients with IPF were classified in two groups according to the 
GAP model. Ley et al. (2012) proposed the GAP model, which is scored by gender, age, 
and lung physiology (%FVC and %DLCO), to discriminate prognosis of patients with 












treatment is proposed according to the disease stage. In GAP stage I, patients may not 
require immediate enlisting for lung transplantation because of the low risk for one-year 
mortality. However, physicians should consider enlisting patients in GAP stage II/III for 
lung transplantation. Therefore, in this study, the differences in FOT results according 
to disease severity were assessed after classifying patients with IPF into GAP stage I or 
stage II/III. 
The usefulness of FOT has been comprehensively investigated in obstructive 
airway diseases, such as bronchial asthma or COPD. The Rrs in FOT, especially in the 
expiratory phase, was reported to reflect the disease status of obstructive airway 
diseases (Ohishi et al., 2011). Conversely, Xrs was believed to be more important for 
the assessment of ILD pathophysiology, as the current study demonstrated. Fujii et al. 
(2015) found that Fres in the inspiratory phase correlated with the FVC, FEV1, DLCO, 
and fibrosis score in ILD. Sugiyama et al. (2013) reported that the presence of ILD was 
associated with ΔX5 and that ΔX5 was negatively correlated with VC and DLCO. 
Although several reports have focused on ILD, patients with ILD are considered to have 
small airway disease in varying degrees, depending on the ILD disease type (Fulmer 
and Roberts, 1980). Therefore, this study included only patients who were strictly 
diagnosed as IPF. 
This study had some limitations. First, the reference values for MostGraph have 
not been established; therefore, the parameters of MostGraph cannot be evaluated 
using percent predicted values. Second, the number of patients who underwent 
multiple measurements was relatively small. Finally, there are FOT equipments other 
than MostGraph used in this study [e.g., Master Screen IOS (Eric Jaeger, Germany)] , 
and slight differences in measured values depending on devices are reported. It is 















The FOT Xrs values, especially in the inspiratory phase, were useful in evaluating 
disease progression in IPF. Even in patients with advanced disease and who have 
difficulty performing PFT, FOT may be performed to noninvasively evaluate disease 
status and predict lung capacity decline. Further prospective studies are required to 
validate the use of Xrs for predicting the prognosis of patients with IPF. 
 
 
Declarations of Competing Interest 
None 
Acknowledgments 
The authors sincerely thank Ms. Atsuko Kuroda of the Department of Laboratory 
Diagnosis, Sapporo Medical University Hospital, Sapporo, Japan, for performing the 
PFT and FOT and for the important advice. The authors also thank Enago 














American Thoracic Society, & European Respiratory Society, 2002. American 
Thoracic Society/European Respiratory Society international multidisciplinary 
consensus classification of the idiopathic interstitial pneumonias. This joint statement 
of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) 
was adopted by the ATS board of directors, June 2001 and by the ERS Executive 
Committee, June 2001. Am. J. Respir. Crit. Care Med. 165, 277–304. 
https://doi.org/10.1164/ajrccm.165.2.ats01.  
Cottin, V., Nunes, H., Brillet, P. Y., Delaval, P., Devouassoux, G., Tillie-Leblond, I., 
Israel-Biet, D., Court-Fortune, I., Valeyre, D., Cordier, J. F., & Groupe d'Etude et de 
Recherche sur les Maladies Orphelines Pulmonaires (GERM O P), 2005. Combined 
pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 
26, 586–593. https://doi.org/10.1183/09031936.05.00021005. 
Dellacà, R. L., Santus, P., Aliverti, A., Stevenson, N., Centanni, S., Macklem, P. T., 
Pedotti, A., & Calverley, P. M. A., 2004. Detection of expiratory flow limitation in 
COPD using the forced oscillation technique. Eur. Respir. J. 23, 232–240. 
https://doi.org/10.1183/09031936.04.00046804. 
Du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., 
King, T. E. Jr, Lancaster, L., Noble, P. W., Sahn, S. A., Thomeer, M., Valeyre, D., & 
Wells, A. U., 2011. Forced vital capacity in patients with idiopathic pulmonary 
fibrosis: test properties and minimal clinically important difference. Am. J. Respir. 
Crit. Care Med. 184, 1382–1389. https://doi.org/10.1164/rccm.201105-0840OC. 
Fujii, M., Shirai, T., Mori, K., Mikamo, M., Shishido, Y., Akita, T., Morita, S., Asada, 












a predictor of the composite physiologic index in interstitial lung disease . Respir. 
Physiol. Neurobiol. 207, 22–27. https://doi.org/10.1016/j.resp.2014.12.009. 
Fulmer, J. D., & Roberts, W. C., 1980. Small airways and interstitial pulmonary 
disease. Chest 77, 470–472. https://doi.org/10.1378/chest.77.4.470. 
King, T. E. Jr, Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, 
I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, 
D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., Noble, P. 
W., & ASCEND Study Group, 2014. A phase 3 trial of pirfenidone in patients with 
idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083–2092. 
https://doi.org/10.1056/NEJMoa1402582. 
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, 
V., Buccioli, M., Elicker, B. M., Jones, K. D., King, T. E. Jr, & Collard, H. R., 2012. A 
multidimensional index and staging system for idiopathic pulmonary fibrosis . Ann. 
Intern. Med. 156, 684–691. https://doi.org/10.7326/0003-4819-156-10-201205150-
00004. 
Martinez, F. J., & Flaherty, K., 2006. Pulmonary function testing in idiopathic 
interstitial pneumonias. Proc. Am. Thorac. Soc. 3, 315–321. 
https://doi.org/10.1513/pats.200602-022TK. 
Mikamo, M., Shirai, T., Mori, K., Shishido, Y., Akita, T., Morita, S., Asada, K., Fujii, 
M., Tsuchiya, T., & Suda, T., 2013. Predictors of phase III slope of nitrogen single-
breath washout in COPD. Respir. Physiol. Neurobiol. 189, 42–46. 
https://doi.org/10.1016/j.resp.2013.06.018. 
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, 
R., Enright, P., van der Grinten, C. P., Gustafsson, P., Jensen, R., Johnson, D. 












G., Wanger, J., & ATS/ERS Task Force; ATS/ERS Task Force, 2005. Standardisation 
of spirometry. Eur. Respir. J. 26, 319–338. 
https://doi.org/10.1183/09031936.05.00034805. 
Natsuizaka, M., Chiba, H., Kuronuma, K., Otsuka, M., Kudo, K., Mori, M., Bando, 
M., Sugiyama, Y., & Takahashi, H., 2014. Epidemiologic Survey of Japanese patients 
with idiopathic pulmonary fibrosis and investigation of ethnic differences . Am. J. 
Respir. Crit. Care Med. 190, 773–779. https://doi.org/10.1164/rccm.201403-0566OC. 
Ohishi, J., Kurosawa, H., Ogawa, H., Irokawa, T., Hida, W., & Kohzuki, M., 2011. 
Application of impulse oscillometry for within-breath analysis in patients with chronic 
obstructive pulmonary disease: pilot study. BMJ Open 1, e000184. 
https://doi.org/10.1136/bmjopen-2011-000184. 
Oostveen, E., MacLeod, D., Lorino, H., Farré, R., Hantos, Z., Desager, K., Marchal, 
F., & ERS Task Force on Respiratory Impedance Measurements; ERS Task Force on 
Respiratory Impedance Measurements, 2003. The forced oscillation technique in 
clinical practice: methodology, recommendations and future developments. Eur. 
Respir. J. 22, 1026–1041. https://doi.org/10.1183/09031936.03.00089403. 
Paredi, P., Goldman, M., Alamen, A., Ausin, P., Usmani, O. S., Pride, N. B., & Barnes, 
P. J., 2010. Comparison of inspiratory and expiratory resistance and reactance in 
patients with asthma and chronic obstructive pulmonary disease. Thorax 65, 263–267. 
https://doi.org/10.1136/thx.2009.120790. 
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. 
V., Cordier, J. F., Flaherty, K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. 
J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, 
M., Hansell, D. M., Johkoh, T., Kim, D. S., King, T. E. Jr, Kondoh, Y., Myers, 












S., Protzko, S. L., Schünemann, H. J., & ATS/ERS/JRS/ALAT Committee on 
Idiopathic Pulmonary Fibrosis, 2011. An official ATS/ERS/JRS/ALAT statement: 
idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and 
management. Am. J. Respir. Crit. Care Med. 183, 788–824. 
https://doi.org/10.1164/rccm.2009-040GL. 
Richeldi, L., Ryerson, C. J., Lee, J. S., Wolters, P. J., Koth, L. L., Ley, B., Elicker, B. 
M., Jones, K. D., King, T. E. Jr, Ryu, J. H., & Collard, H. R., 2012. Relative versus 
absolute change in forced vital capacity in idiopathic pulmonary fibrosis . Thorax 67, 
407–411. https://doi.org/10.1136/thoraxjnl-2011-201184. 
Shirai, T., & Kurosawa, H., 2016. Clinical application of the forced oscillation 
technique. Intern. Med. 55, 559–566. 
https://doi.org/10.2169/internalmedicine.55.5876. 
Shirai, T., Mori, K., Mikamo, M., Shishido, Y., Akita, T., Morita, S., Asada, K., Fujii, 
M., Suda, T., & Chida, K., 2013. Respiratory mechanics and peripheral airway 
inflammation and dysfunction in asthma. Clin. Exp. Allergy 43, 521–526. 
https://doi.org/10.1111/cea.12083. 
Sugiyama, A., Hattori, N., Haruta, Y., Nakamura, I., Nakagawa, M., Miyamoto, 
S., Onari, Y., Iwamoto, H., Ishikawa, N., Fujitaka, K., Murai, H., & Kohno, N., 2013. 
Characteristics of inspiratory and expiratory reactance in interstitial lung disease . 
Respir. Med. 107, 875–882. https://doi.org/10.1016/j.rmed.2013.03.005. 
van Noord, J. A., Clément, J., Cauberghs, M., Mertens, I., Van de Woestijne, K. P., & 
Demedts, M., 1989. Total respiratory resistance and reactance in patients with diffuse 





























Figure 1. Correlation between FVC/%FVC and Xrs in the inspiratory phase . 
X5 (In) has significant positive correlations with FVC and %FVC. Fres (In) and ALX 






































ALX (In), low-f requency reactance area in the 
inspiratory phase; Fres (In), resonant frequency in the 
inspiratory phase; FVC, forced vital capacity; %FVC, 
forced vital capacity % predicted; Xrs, respiratory system 
reactance; X5 (In), respiratory system reactance at 5Hz in 













Table 1.  Baseline characteristics,  pulmonary function tests , and the FOT 
parameters  
  IPF (n = 97) 
Age  72 (67–77) 
Sex Men/Women 73 / 24 
Body mass index 23.5 (21.5–25.9) 
Smoking 
78 / 19 Current or 
former/never 
Brinkman index 700 (150–1010) 
VC (L) 2.58 (2.12–3.18) 
%VC 87.6 (74.6–99.7) 
FVC (L) 2.54 (2.04–3.12) 
%FVC 86.0 (71.1–98.1) 
FEV1 (L) 2.09 (1.74–2.45) 




$ %DLCO 53.4 (43.6–63.0) 
R5 (cmH2O/L/s)  
 Whole breath 2.86 (2.35–3.72) 
 Ex 3.20 (2.61–4.08) 
In 2.69 (2.11–3.25) 
ΔR5 0.46 (0.18–0.92) 
R20 (cmH2O/L/s)  
 Whole breath 2.17 (1.82–2.78) 
 Ex 2.22 (1.82–2.92) 











ΔR20 0.17 (−0.08–0.51) 
R5–R20 (cmH2O/L/s)  
 Whole breath 0.69 (0.40–0.97) 
 Ex 0.86 (0.45–1.18) 
 In 0.49 (0.32–0.78) 
ΔR5–R20 0.29 (0.12–0.53) 
X5 (cmH2O/L/s)  
 Whole breath −0.96 (−1.17–−0.48) 
 Ex −0.97 (−1.28–−0.42) 
 In −0.83 (−1.19–−0.53) 
ΔX5 0.04 (−0.17–0.18) 
Fres (Hz)  
 Whole breath 10.4 (7.89–12.2) 
 Ex 10.1 (7.27–12.3) 
 In 10.3 (8.16–12.0) 
ΔFres −0.30 (−1.14–0.75) 
ALX (cmH2O/L/s)  
Whole breath 3.90 (1.72–5.81) 
Ex 4.02 (1.34–6.11) 
 In 3.52 (1.85–5.75) 
ΔALX −0.28 (−0.77–1.03) 
Data are presented as median ( IQR).  
p  values were calculated using the Chi square test or Mann–Whitney U 
test .  
$DLCO was measured in 84 cases.  
 
ALX, low-frequency reactance area;  Δ, difference between expiratory 
and inspiratory phases; DLCO, diffusing capacity of the lung for carbon 
monoxide; Ex, expiratory phase; FEV1, forced expiratory volume in one 











FVC, forced vital  capacity;  In, inspiratory phase;  IPF, idiopathic 
pulmonary fibrosis;  Rrs,  respiratory system resistance; R5, Rrs at 5 Hz; 
R20, Rrs at  20 Hz; R5–R20, difference between R5 and R20; VC, vital 













Table 2.  Correlations between the values of PFT and FOT in patients with IPF  
  VC %VC FVC %FVC FEV1 FEV1/FVC $ DLCO  $ %DLCO 
R5 Whole breath −0.358* −0.065  −0.365* −0.085  −0.500* −0.223# −0.089  0.066  
R5 Ex −0.324* −0.041  −0.333* −0.060  −0.475* −0.235# −0.052  0.098  
R5 In −0.354* −0.052  −0.358* −0.071  −0.472* −0.195  −0.130  0.024  
ΔR5 −0.126 0.013  −0.133  0.004  −0.260# −0.205# 0.008  0.082  
R20 Whole breath −0.359* −0.058  −0.362* −0.075  −0.492* −0.246# −0.085  0.049  
R20 Ex −0.335* −0.024  −0.342* −0.045  −0.483* −0.271* −0.076  0.067  
R20 In −0.301* −0.018  −0.300* −0.036  −0.411* −0.230# −0.093  0.020  
ΔR20 −0.184 −0.035  −0.198  −0.049  −0.305* −0.177  −0.007  0.093  
R5–R20 Whole 
breath 
−0.244# −0.113  −0.255# −0.131  −0.331* −0.047  −0.057  0.069  
R5–R20 Ex −0.161 −0.042  −0.171  −0.064  −0.247# −0.052  −0.036  0.068  
R5–R20 In −0.321* −0.181  −0.330* −0.191  −0.386* −0.017  −0.142  −0.006  
ΔR5–R20 0.055 0.144  0.060  0.149  −0.035  −0.183  0.019  0.040  
 VC %VC FVC %FVC FEV1 FEV1/FVC $ DLCO $ %DLCO 
X5 Whole breath 0.556* 0.533* 0.536* 0.509* 0.514* −0.241# 0.297* 0.197  











X5 In 0.613* 0.596* 0.596* 0.568* 0.532* −0.347* 0.350* 0.242# 
ΔX5 −0.048 −0.072  −0.052  −0.070  0.063  0.271* −0.084  −0.101  
Fres Whole breath −0.494* −0.526* −0.477* −0.498* −0.433* 0.273* −0.256# −0.148  
Fres Ex −0.403* −0.435* −0.384* −0.407* −0.375* 0.171  −0.173  −0.081  
Fres In −0.552* −0.607* −0.537* −0.575* −0.462* 0.366* −0.317* −0.207  
ΔFres 0.051 0.088  0.069  0.104  −0.032 −0.284* 0.093  0.108  
ALX Whole breath −0.543* −0.533* −0.525* −0.510* −0.501* 0.251# −0.284* −0.181  
ALX Ex −0.441* −0.424* −0.424* −0.405* −0.440* 0.127  −0.201  −0.116  
ALX In −0.612* −0.611* −0.595* −0.581* −0.526* 0.360* −0.354* −0.244# 
ΔALX 0.168 0.196  0.170  0.190  0.030  −0.387* 0.144  0.144  
Values are presented as correlation coefficients. 
*p value <0.01, # p value <0.05. 
$DLCO was measured in 84 cases. 
 
ALX, low-frequency reactance area;  Δ, difference between expiratory and inspiratory phases;  DLCO, diffusing 
capacity of the lung for carbon monoxide; Ex, expiratory phase; FEV1, forced expiratory volume in one second; 
FOT, forced oscil lat ion technique; Fres, resonant freque ncy; FVC, forced vital  capacity; In, inspiratory phase; 
IPF, idiopathic pulmonary fibrosis; PFT, pulmonary function test; Rrs,  respiratory system resistance; R5, Rrs at 5 Hz; 
R20, Rrs at  20 Hz; R5–R20, difference between R5 and R20; VC, vital capacity;  Xrs , respiratory system 











Table 3.  Comparison of the values of PFT and FOT according to the GAP 
disease stage  
  GAP stage I  
(n = 47) 
GAP stage II/III  
(n = 50) 
p value 
VC (L) 2.88 (2.49–3.35) 2.35 (2.00–2.85) <0.001 
%VC 96.5 (87.2–108.5) 74.7 (67.2–90.4) <0.001 
FVC (L) 2.90 (2.41–3.33) 2.23 (1.89–2.84) <0.001 
%FVC 95.1 (84.6–104.8) 71.2 (64.2–90.8) <0.001 
FEV1 (L) 2.32 (1.90–2.64) 1.93 (1.53–2.26) 0.001 
FEV1 / FVC (%) 81.5 (77.5–85.1) 84.1 (80.8–89.4) 0.041 
$ DLCO 
(mL/min/mmHg) 
12.9 (10.3–16.5) 9.36 (7.28–10.9) <0.001 
$ %DLCO 61.1 (53.3–71.3) 45.3 (35.3–52.2) <0.001 
R5 (cmH2O/L/s)    
Whole breath 2.93 (2.31–4.02) 2.79 (2.46–3.42) 0.532 
 Ex 3.24 (2.62–4.50) 2.87 (2.58–3.86) 0.402 
 In 2.73 (2.01–3.61) 2.64 (2.14–3.08) 0.528 
ΔR5 0.49 (0.18–1.09) 0.42 (0.17–0.87) 0.495 
R20 (cmH2O/L/s)    
 Whole breath 2.26 (1.79–2.95) 2.16 (1.84–2.65) 0.636  
 Ex 2.34 (1.81–3.10) 2.14 (1.86–2.89) 0.537  
 In 2.19 (1.70–2.78) 2.02 (1.79–2.34) 0.457  
ΔR20 0.13 (−0.08–0.50) 0.19 (−0.07–0.51) 0.905  
R5–R20 (cmH2O/L/s)    
 Whole breath 0.67 (0.35–1.04) 0.72 (0.42–0.94) 0.707  
 Ex 0.88 (0.44–1.24) 0.84 (0.44–1.06) 0.410  
 In 0.47 (0.30–0.84) 0.53 (0.35–0.75) 0.634  
ΔR5–R20 0.32 (0.13–0.69) 0.25 (0.03–0.44) 0.082  
X5 (cmH2O/L/s)    











 Ex −0.79 (−1.18–−0.34) −1.08 (−1.49–−0.53) 0.082  
 In −0.73 (−1.08–−0.37) −1.08 (−1.33–−0.73) 0.005  
ΔX5 0.03 (−0.33–0.18) 0.05 (−0.11–0.18) 0.593  
Fres (Hz)    
 Whole breath 9.24 (7.23–11.2) 11.6 (8.97–12.7) 0.007  
 Ex 9.61 (6.86–11.7) 11.6 (8.47–13.2) 0.038  
 In 9.50 (6.94–11.0) 11.6 (9.43–12.6) 0.001  
ΔFres −0.46 (−1.13–0.98) −0.28 (−1.28–0.25) 0.400  
ALX (cmH2O/L/s)    
 Whole breath 3.20 (1.23–4.71) 5.31 (2.58–7.14) 0.009  
 Ex 3.16 (1.06–5.37) 5.01 (1.94–7.70) 0.065  
 In 2.84 (1.25–4.55) 5.21 (2.76–6.60) 0.003  
ΔALX −0.25 (−0.81–2.15) −0.33 (−0.78–0.60) 0.354  
Data are presented as median ( IQR). 
p  values were calculated using the Mann–Whitney U test .  
$DLCO was measured in 37 cases in GAP stage II/  III.  
 
ALX, low-frequency reactance area;  Δ, difference between expiratory and 
inspiratory phases; DLCO, diffusing capacity of the lung for carbon 
monoxide; Ex, expiratory phase; FEV1, forced expirato ry volume in one 
second; FOT, forced oscillation technique; Fres,  resonant frequency; FVC, 
forced vital capacity; GAP, gender, age, and physiologic variables; In,  
inspiratory phase; IPF, idiopathic pulmonary fibrosis; PFT, pulmonary function 
test; Rrs, respiratory system resistance; R5, Rrs at 5 Hz; R20, Rrs at 20 Hz; 
R5–R20, difference between R5 and R20; VC, vital  capacity;  Xrs, respiratory 

















Table 4.  Comparison of the initial and second measurement values of PFT and 
FOT in IPF patients (n = 41) 
  Initial values Second values p value 
VC (L) 2.73 (2.12–3.29) 2.52 (1.92–3.15) <0.001 
%VC 90.9 (75.8–104.0) 86.7 (71.7–101.7) <0.001 
FVC (L) 2.79 (2.04–3.29) 2.45 (1.85–3.11) <0.001 
%FVC 90.5 (75.4–101.5) 85.5 (71.4–100.5) <0.001 
FEV1 (L) 2.29 (1.77–2.49) 2.00 (1.63–2.48) 0.005  
FEV1 / FVC (%) 81.8 (76.8–84.7) 83.8 (77.4–88.3) 0.020  
$ DLCO 
(mL/min/mmHg) 
11.0 (9.05–14.8) 10.8 (7.74–13.8) 0.001 
$ %DLCO 53.6 (44.6–67.2) 53.8 (38.2–65.3) 0.006  
R5 (cmH2O/L/s)    
 Whole breath 2.98 (2.30–3.75) 3.19 (2.41–3.70) 0.871  
 Ex 3.20 (2.62–4.25) 3.30 (2.48–4.16) 0.938  
 In 2.70 (2.03–3.18) 2.82 (2.18–3.48) 0.707  
ΔR5 0.46 (0.20–1.07) 0.52 (0.14–1.07) 0.555  
R20 (cmH2O/L/s)    
 Whole breath 2.16 (1.80–3.09) 2.10 (1.87–2.75) 0.559  
 Ex 2.22 (1.82–3.14) 2.30 (1.82–2.95) 0.746  
 In 2.03 (1.71–2.66) 2.08 (1.67–2.72) 0.659  
ΔR20 0.12 (−0.07–0.60) 0.25 (−0.07–0.57) 0.783  
R5–R20 (cmH2O/L/s)    
 Whole breath 0.68 (0.35–0.97) 0.80 (0.55–1.15) 0.403  
 Ex 0.86 (0.43–1.08) 1.00 (0.57–1.38) 0.513  
 In 0.49 (0.32–0.86) 0.67 (0.42–0.81) 0.361  
ΔR5–R20 0.26 (0.12–0.52) 0.31 (0.10–0.57) 0.953  
X5 (cmH2O/L/s)    
 Whole breath −0.82 (−1.09–−0.29) −0.92 (−1.43–−0.47) 0.005 











 In −0.74 (−1.12–−0.36) −0.80 (−1.42–−0.55) <0.001 
ΔX5 0.10 (−0.17–0.24) 0.14 (−0.41–0.27) 0.707 
Fres (Hz)    
 Whole breath 9.67 (6.43–11.3) 10.4 (7.93–13.2) <0.001 
 Ex 9.48 (6.44–11.5) 10.2 (7.41–13.1) 0.001 
 In 9.80 (7.18–11.5) 10.5 (8.40–12.9) <0.001 
ΔFres −0.79 (−1.35–0.58) −0.35 (−1.55–1.11) 0.492 
ALX (cmH2O/L/s)    
 Whole breath 3.28 (1.00–5.10) 3.99 (1.62–7.45) 0.001 
 Ex 2.78 (0.79–5.12) 3.46 (1.23–7.76) 0.008 
 In 3.01 (1.14–5.31) 3.61 (1.97–7.75) <0.001 
ΔALX −0.36 (−1.16–0.64) −0.58 (−1.53–1.75) 0.425 
Data are presented as median ( IQR). 
p  values were calculated using the Wilcoxon signed -rank test.  
$DLCO was measured in 36 cases.  
 
ALX, low-frequency reactance area;  Δ, difference between expiratory and 
inspiratory phases; DLCO, diffusing capacity of the lung for carbon 
monoxide; Ex, expiratory phase; FEV1, forced expiratory volume in one 
second; FOT, forced oscillation technique; Fres,  resonant frequency; FVC, 
forced vital capacity; GAP, gender, age, and physiologic variables; In,  
inspiratory phase; IPF, idiopathic pulmonary fibrosis; PFT, pulmonary function 
test; Rrs, respiratory system resistance; R5, Rrs at 5 Hz; R20, Rrs at 20 Hz; 
R5–R20, difference between R5 and R20; VC, vital  capacity;  Xrs, respiratory 

















Table 5.  Univariate logistic regression analysis of the factors that  p redicted 
10% or more decline in FVC within 12 months  
 Odds ratio 95% CI p value 
Age 1.045 0.946–1.560 0.386 
Sex 2.610  0.475–14.25 0.270  
Smoking 1.370  0.238–7.883 0.725  
DLCO 0.858  0.674–1.092 0.213  
%DLCO 0.968  0.917–1.022 0.243  
R5 Whole breath 1.073  0.544–2.115 0.840  
R5 Ex 1.084  0.613–1.916 0.782  
R5 In 0.690  0.314–1.514 0.354  
ΔR5 1.930  0.734–5.072 0.182*  
R20 Whole breath 0.847  0.343–2.094 0.719  
R20 Ex 0.849  0.379–1.899 0.690  
R20 In 0.423  0.137–1.306 0.135*  
ΔR20 2.431  0.475–12.45 0.287  
R5–R20 Whole breath 1.891  0.548–6.527 0.314  
R5–R20 Ex 1.499  0.541–4.159 0.436  
R5–R20 In 2.580  0.577–11.54 0.215 
ΔR5–R20 0.676  0.072–6.381 0.732  
X5 Whole breath 0.411  0.166–1.016 0.054* 
X5 Ex 0.566  0.289–1.110 0.098* 
X5 In 0.271  0.079–0.936 0.039* 
ΔX5 0.799  0.278–2.294 0.676  
Fres Whole breath 1.296  0.995–1.687 0.055* 
Fres Ex 1.198  0.962–1.493 0.107* 
Fres In 1.395  1.029–1.891 0.032* 
ΔFres 0.851  0.523–1.387 0.518  
ALX Whole breath 1.146  0.992–1.325 0.065* 











*p  value <0.20. 
 
ALX, low-frequency reactance area; CI, confidence interval;  Δ, difference 
between expiratory and inspiratory phases; DLCO, diffusing capacity of the 
lung for carbon monoxide; Ex, expiratory phase; Fres, resonant frequency; 
FVC, forced vital  capacity;  In, inspiratory phase;  Rrs, respiratory system 
resistance; R5, Rrs at 5 Hz; R20, Rrs at  20 Hz; R5–R20, difference between 





















ALX In 1.240  1.005–1.5029 0.044* 











Table 6.  Multivariate logistic regression analysis of the factors that predicted 
10% or more decline in FVC within 12 months  
 
 Odds ratio 95% CI p value 
ΔR5 1.336 0.351–5.092 0.671 
R20 In 0.218 0.042–1.117 0.068 
X5 In 0.137 0.021–0.875 0.036* 
*p  value <0.05.  
 
CI, confidence interval;  Δ, difference between expiratory and inspiratory 
phases; FVC, forced vital  capacity;  In,  inspiratory phase;  R5, respiratory 
system resistance at 5 Hz; R20, respiratory system resistance at 20 Hz; X5, 
respiratory system reactance at  5 Hz.  
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